Medicare AdvantageAugust 14, 2023
Clinical Criteria updates - May 2023
On December 22, 2022, May 2, 2023, and May 19, 2023, the Pharmacy and Therapeutic (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Anthem Blue Cross and Blue Shield (Anthem). These policies were developed, revised, or reviewed to support clinical coding edits.
Visit Clinical Criteria to search for specific policies. If you have questions or need additional information, use this email.
Please see the explanation/definition for each category of Clinical Criteria below:
- New: Newly published criteria
- Revised: Addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive.
Please share this notice with other providers in your practice and office staff.
Please note:
- The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
- This notice is meant to inform the provider of new or revised criteria that has been adopted by Anthem only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.
Effective date | Clinical Criteria number | Clinical Criteria title | New or revised |
September 18, 2023 | *CC-0237 | Qalsody (tofersen) | New |
September 18, 2023 | *CC-0238 | Hydroxyprogesterone caproate | New |
September 18, 2023 | *CC-0240 | Zynyz (retifanlimab-dlwr) | New |
September 18, 2023 | CC-0165 | Trodelvy (sacituzumab govitecan) | Revised |
September 18, 2023 | CC-0002 | Colony Stimulating Factor Agents | Revised |
September 18, 2023 | CC-0128 | Tecentriq (atezolizumab) | Revised |
September 18, 2023 | CC-0098 | Doxorubicin Liposome (Doxil, Lipodox) | Revised |
September 18, 2023 | CC-0101 | Torisel (temsirolimus) | Revised |
September 18, 2023 | CC-0107 | Bevacizumab for Non-Ophthalmologic Indications | Revised |
September 18, 2023 | CC-0143 | Polivy (polatuzumab vedotin-piiq) | Revised |
September 18, 2023 | CC-0092 | Adcetris (brentuximab vedotin) | Revised |
September 18, 2023 | CC-0095 | Velcade (bortezomib) | Revised |
September 18, 2023 | CC-0105 | Vectibix (panitumumab) | Revised |
September 18, 2023 | CC-0178 | Synribo (omacetaxine mepesuccinate) | Revised |
September 18, 2023 | CC-0114 | Jevtana (cabazitaxel) | Revised |
September 18, 2023 | CC-0145 | Libtayo (cemiplimab-rwlc) | Revised |
September 18, 2023 | *CC-0032 | Botulinum Toxin | Revised |
September 18, 2023 | CC-0068 | Growth Hormone | Revised |
September 18, 2023 | *CC-0057 | Krystexxa (pegloticase) | Revised |
September 18, 2023 | *CC-0125 | Opdivo (nivolumab) | Revised |
September 18, 2023 | *CC-0225 | Tzield (teplizumab-mzwv) | Revised |
September 18, 2023 | *CC-0124 | Keytruda (pembrolizumab) | Revised |
MULTI-BCBS-CR-031946-23-CPN30755
PUBLICATIONS: September 2023 Provider Newsletter
To view this article online:
Visit https://providernews.anthem.com/missouri/articles/clinical-criteria-updates-may-2023-14-15044
Or scan this QR code with your phone